12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin inhibitors In Mixed Lineage Leukemias
11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
